American Gene Technologies Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $310K

  • Investors
  • 14

American Gene Technologies General Information

Description

Developer of gene and cell therapy designed to cure infectious diseases, cancers, and inherited disorders. The company's therapy has three patents to make the cell product functionally cure HIV individuals, and ten patents for its immuno-oncology approach to stimulate gamma-delta T cells to eliminate a variety of human solid tumors has developed a synthetic gene, enabling physicians to get effective drugs to treat Phenylketonuria (PKU) patients.

Contact Information

Formerly Known As
American Gene Technologies International
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9713 Key West Avenue
  • 5th Floor
  • Rockville, MD 20850
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 9713 Key West Avenue
  • 5th Floor
  • Rockville, MD 20850
  • United States
+1 (301)

American Gene Technologies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

American Gene Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 22-Dec-2025 $310K Completed Clinical Trials - General
12. Later Stage VC 21-Jan-2025 Completed Clinical Trials - General
11. Later Stage VC (Series F) 30-Apr-2022 Completed Clinical Trials - General
10. Later Stage VC (Series E2) 14-Mar-2021 Completed Clinical Trials - General
9. Angel (individual) 01-Sep-2020 Completed Clinical Trials - General
8. Debt - PPP 13-Apr-2020 Completed Clinical Trials - General
7. Later Stage VC (Series E1) 14-Feb-2019 Completed Generating Revenue
6. Later Stage VC (Series D1) 30-Nov-2018 Completed Generating Revenue
5. Later Stage VC (Series C1) 26-Apr-2016 $4.1M $6.9M Completed Generating Revenue
4. Seed Round 30-Apr-2015 $1.8M $2.8M Completed Generating Revenue
To view American Gene Technologies’s complete valuation and funding history, request access »

American Gene Technologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E1
Series D1
Series C1
Series B1 4,166,666 $0.000100 $0.04 $0.48 $0.48 1x $0.48 7.86%
Series A1 2,170,610 $0.000100 $0.04 $0.46 $0.46 1x $0.46 4.1%
To view American Gene Technologies’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

American Gene Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene and cell therapy designed to cure infectious diseases, cancers, and inherited disorders. The company's
Drug Discovery
Rockville, MD
25 As of 2025

South San Francisco, CA
 

Lyon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

American Gene Technologies Competitors (94)

One of American Gene Technologies’s 94 competitors is Senti Biosciences Holdings, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Senti Biosciences Holdings Formerly VC-backed South San Francisco, CA
Phaxiam Formerly VC-backed Lyon, France
Orchard Therapeutics Formerly VC-backed London, United Kingdom
Immusoft Venture Capital-Backed Seattle, WA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 94 competitors. Get the full list »

American Gene Technologies Patents

American Gene Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4780472-A2 Hiv vaccination and immunotherapy Pending 22-Sep-2023
WO-2025064901-A2 Hiv vaccination and immunotherapy Inactive 22-Sep-2023
WO-2025064901-A3 Hiv vaccination and immunotherapy Inactive 22-Sep-2023
WO-2025050047-A1 Combination immunotherapy and antiviral treatment Inactive 01-Sep-2023
AU-2022211039-A1 Engineered nk cells and methods of treating cancer Pending 21-Jan-2021 A61K40/15
To view American Gene Technologies’s complete patent history, request access »

American Gene Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

American Gene Technologies Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Carat Venture Partners Venture Capital Minority
MCMA Ventures Venture Capital Minority
Opus8 PE/Buyout Minority
Ossian Capital Venture Capital Minority
Ride Wave Ventures Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

American Gene Technologies FAQs

  • When was American Gene Technologies founded?

    American Gene Technologies was founded in 2007.

  • Where is American Gene Technologies headquartered?

    American Gene Technologies is headquartered in Rockville, MD.

  • What is the size of American Gene Technologies?

    American Gene Technologies has 25 total employees.

  • What industry is American Gene Technologies in?

    American Gene Technologies’s primary industry is Drug Discovery.

  • Is American Gene Technologies a private or public company?

    American Gene Technologies is a Private company.

  • What is American Gene Technologies’s current revenue?

    The current revenue for American Gene Technologies is .

  • How much funding has American Gene Technologies raised over time?

    American Gene Technologies has raised $81.3M.

  • Who are American Gene Technologies’s investors?

    Carat Venture Partners, MCMA Ventures, Opus8, Ossian Capital, and Ride Wave Ventures are 5 of 14 investors who have invested in American Gene Technologies.

  • Who are American Gene Technologies’s competitors?

    Senti Biosciences Holdings, Phaxiam, Orchard Therapeutics, Immusoft, and Inovio Pharmaceuticals are some of the 94 competitors of American Gene Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process